Cas:123572-88-3 furametpyr manufacturer & supplier

Chemical Name:furametpyr

CAS.NO:123572-88-3

Synonyms:N-(1,3-dihydro-1,1,3-trimethylisobenzofuran-4-yl)-5-chloro-1,3-dimethylpyrazole-4-carboxamide;Limber;5-chloro-N-(1,3-dihydro-1,1,3-trimethyl-4-isobenzofuranyl)-1,3-dimethyl-(9CI);N-(1,1,3-trimethyl-2-oxa-4-indanyl)-5-chloro-1,3-dimethylpyrazole-4-carboxamide;1H-Pyrazole-4-carboxamide,5-chloro-N-(1,3-dihydro-1,1,3-trimethyl-4-isobenzofuranyl)-1,3-dimethyl;rac-5-chloro-1,3-dimethyl-N-[(1R)-1,1,3-trimethyl-1,3-dihydro-2-benzofuran-4-yl]-1H-pyrazole-4-carboxamide;Furametpyr [ISO:BSI];5-chloro-1,3-dimethyl-N-(1,1,3-trimethyl-3H-2-benzofuran-4-yl)pyrazole-4-carboxamide;5-chloro-N-(1,3-dihydro-1,1,3-trimethyl-4-isobenzofuranyl)-1,3-dimethylpyrazole-4-carboxamide;(RS)-5-chloro-N-(1,3-dihydro-1,1,3-trimethylisobenzofuran-4-yl)-1,3-dimethylpyrazole-4-carboxamide;Furametpyr;5-chloro-N-(1,3-dihydro-1,1,3-trimethyl-4-isobenzofuranyl)-1,3-dimethyl-1H-pyrazole-4-carboxamide

Molecular Formula:C₁₇H₂₀ClN₃O₂

Molecular Weight:333.81300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:399.4ºC at 760 mmHg

Density:1.3g/cm3

Index of Refraction:1.621

PSA:56.15000

Exact Mass:333.12400

LogP:4.03350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(1,3-dihydro-1,1,3-trimethylisobenzofuran-4-yl)-5-chloro-1,3-dimethylpyrazole-4-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-chloro-N-(1,3-dihydro-1,1,3-trimethyl-4-isobenzofuranyl)-1,3-dimethyl-1H-pyrazole-4-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(1,1,3-trimethyl-2-oxa-4-indanyl)-5-chloro-1,3-dimethylpyrazole-4-carboxamide Use and application,5-chloro-N-(1,3-dihydro-1,1,3-trimethyl-4-isobenzofuranyl)-1,3-dimethylpyrazole-4-carboxamide technical grade,usp/ep/jp grade.

Related News: In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. furametpyr manufacturer At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. furametpyr supplier It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. furametpyr vendor At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. furametpyr factory It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer.